ESR1 and breast carcinoma: As a kind of classical SERM, fulvestrant inhibits growth-stimulating effects of ERβ by negatively regulating DNA methyltransferase (DNMT), widening the scope of the intent-to-treat population to ERα-/ERβ+ breast cancer (40).